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osting by EAbstract Ghrelin is a novel gastrointestinal peptide hormone isolated from human and rat stom-
ach. Ghrelin administration stimulates growth hormone secretion but also causes weight gain by
increasing food intake and reducing fat utilization in rodents. This study aims to determine the
plasma level of ghrelin under basal condition and in response to a standard meal and to elucidate
the relationship between this peptide and anthropometric measures. Body mass index (BMI),
anthropometric measurements were calculated and plasma ghrelin concentrations were determined
in 122 obese, overweight and lean Saudi females before and an hour after breakfast. Fasting ghrelin
was signiﬁcantly higher in lean than in obese and overweight subjects and fall after eating in the lean
group. There was slight insigniﬁcant reduction in circulating ghrelin of the obese and overweight
groups. Ghrelin levels were negatively correlated with BMI in obese, overweight and lean subjects.
Obese subjects do not exhibit the decline in plasma ghrelin seen after a meal in the lean; the lack of
suppression following a meal in obese subjects could lead to increased food consumption and sug-
gest that ghrelin may be involved in the pathphysiology of obesity.
ª 2009 King Saud University. All rights reserved.1. Introduction
Obesity is a major global epidemic problem (Bray, 2005).
It concerns about 35.5% of Saudi adult population
(Al-Nozha et al., 2005; Al-Othaimeen et al., 2007). Obesity isity. All rights reserved. Peer-
d University.
lseviera multifactorial disease with genetic, endocrinal and environ-
mental origins (Bouchard, 1994; Daghestani et al., 2007),
resulting from an imbalance between energy intake and
expenditure.
Ghrelin, the endogenous ligand for the growth hormone
secretagogue receptor (GHSR) (Sun et al., 2007), is a 28-ami-
no-acid peptide that is secreted primarily by cells in the oxyntic
glands of the stomach as well as in the intestine (Date et al.,
2000). It has been reported to have endocrine and nonendo-
crine actions (Abiko et al., 2005; Allison et al., 2005;
Leite-Moreira et al., 2008; Taub, 2008). Ghrelin is a circulating
orexigen (Pazos et al., 2008), and food intake increases after
administration of exogenous ghrelin in both rodents and
humans (Tschop et al., 2000; Wren et al., 2001). Consistent
120 M.H. Daghestaniwith a physiological role for ghrelin in feeding behavior, the
administration of antighrelin antibodies or GH secretagogue
receptor antagonists reduces food intake (Nakazato et al.,
2001). Changes in plasma ghrelin levels might therefore pro-
duce important differences in food intake and energy balance
and play a signiﬁcant role in the pathogenesis of obesity
(Soriano-Guille´n et al., 2004). Ghrelin levels are reported to
be increased in Anorexia nervosa (Otto et al., 2001) and after
fasting (Muller et al., 2002), whereas in obese patients (Tschop
et al., 2001a) and after feeding they are decreased (Tscho¨p
et al., 2001b; English et al., 2002). These data suggest that
ghrelin plays an important endocrine role linking the periphe-
ral mechanisms regulating caloric intake with hypothalamic
centers that control energy balance (Muccioli et al., 2002).
This study aims to determine the plasma level of ghrelin un-
der basal condition and in response to a standard meal and to
elucidate the relationship between this peptide and anthropo-
metric measures in Saudi females.
2. Material and methods
2.1. Subjects
A total of 122 Saudi females volunteers were recruited, aged
20–30 years (mean ± SEM). The subjects were divided into
three groups according to their body mass index (BMI); lean
(n= 60, BMI 18.5–24 kg/m2), overweight (n= 17, BMI 25–
29 kg/m2) and obese (n= 45, BMIP30 kg/m2). BMI for dif-
ferent groups was determined according to the criteria of the
World Health Organization (WHO, 2000). The general charac-
teristics of the subjects are summarized in Table 1. All subjects
were healthy, free of any medication with regular menstrual
cycle, and no history of gastrointestinal or endocrine disorders.
Ethical approval was obtained from KFSH&RC Research
Ethical committees, and written informed consent was ob-
tained from all subjects.
2.2. Protocol
After an overnight fasting (12 h) 5 ml venous blood samples
were obtained from all subjects in the morning between
08.00 h and 09.00 h by venipuncture. Following fast blood
sample collection, subjects consumed a standard mixed break-
fast of about 527 kcal during 15 min. The meal consisted of
50 g white bread, 33 g black bread, 18 g margarine, 30 g
cheese, 9 g jam and 200 ml of 0.5% fat milk (24.1% fat,
54.4% carbohydrate, 21.5% protein). Blood samples were
collected 60 min after the meal ingestion. The samples were
collected into chilled tubes containing 1.2 mg EDTA andTable 1 Baseline characteristics of participants.
Variables Control lean (n= 60) Overw
Age (yr) 23.95 ± 0.60 21.59
BMI (kg/m2) 20.85 ± 0.25 27.38
Waist (cm) 66.85 ± 0.70 81.59
Hip (cm) 94.59 ± 0.91 105.29
WH ratio 0.71 ± 0.01 0.78
Fasting ghrelin (ng/ml) 0.57 ± 0.02 0.44
Postprandial ghrelin (ng/ml) 0.30 ± 0.01 0.41
Note: values are expressed as mean ± SE, BMI (body mass index), WH raprotinin (500 KIU/ml; Trasylol; Bayer Corp., Leverkusen,
Germany) for hormone analyses. All samples were kept in
an ice bath until centrifugation at 3000 rpm for 15 min at
4 C. Plasma was isolated and stored at 80 C until analysis.
2.3. Anthropometric measurements
Measurements were performed after an overnight fast. Body
mass was measured on calibrated balances or electronic scales
to the nearest 0.1 kg. Body height was measured to the nearest
centimetre. BMI was calculated as body mass (kilograms) di-
vided by body height (meters) squared. Using a tape measure,
with the subject standing, the waist was measured as the nar-
rowest circumference between the lower costal margin and
the iliac crest. The hip was the maximum circumference at
the level of the femoral trochanters.
2.4. Analytical method
Serum ghrelin levels were measured in duplicate using a com-
mercial ghrelin (human) enzyme immunoassay kit (EIA) from
(Phoenix Pharma-ceuticals, INc (Belmont, CA)) with a lower
limit of detection of 0.06 ng/ml.
2.5. Statistical analysis
The descriptive characteristics of the group variables were ex-
pressed as mean ± SEM. The comparisons among overweight,
obese and their lean matched control were done using the inde-
pendent t-test with respect to all variables. Pearson Correlation
Coefﬁcient was used to ﬁnd the correlation between ghrelin
and other studied variables. Signiﬁcance was declared when
P-values are less than 0.05. All statistical analyses were per-
formed using the StatView program for Windows (version
8.0; SAS Institute, Inc., Cary, NC).
3. Results
The mean age, BMI, anthropometric, mean ghrelin concentra-
tions of the groups are shown in Table 1.
As presented in Table 1 Student’s t-test was applied and sig-
niﬁcant differences were found in the waist, hip and waist/hip
ratio among overweight and obese subjects compared with
lean control group.
The fasting ghrelin level was generally decreasing with
increasing body weight, it was evident that the levels were
remarkably higher among lean females if they were compared
with the overweight and obese groups, these differences were
statistically signiﬁcant P< 0.001 (Table 1). The mean fastingeight (n= 17) P-value Obese (n= 45) P-value
± 0.94 NS 26.49 ± 0.96 0.03
± 0.37 <.0001 35.90 ± 0.92 <.0001
± 1.82 <.0001 100.29 ± 2.14 <.0001
± 1.78 <.0001 121.96 ± 2.14 <.0001
± 0.01 <.0001 0.82 ± 0.01 <.0001
± 0.02 <.0001 0.28 ± 0.01 <.0001
± 0.02 <.001 0.27 ± 0.01 0.02
atio (waist hip ratio), NS (nonsigniﬁcant). P-level by Student’s t-test.
Table 2 Correlation between fasting ghrelin and different parameters in lean, overweight and obese groups.
Variables Lean control group Overweight group Obese group
r P r P r P
Age (yr) 0.310 0.018 0.032 0.904 0.0159 0.9175
BMI (kg/m2) 0.616 <.0001 0.583 0.014 0.8102 <.0001
Waist (cm) 0.490 <.0001 0.353 0.165 0.692 <.0001
Hip (cm) 0.492 <.0001 0.549 0.022 0.718 <.0001
WH ratio 0.041 0.758 0.0204 0.938 0.212 0.162
A preprandial and postprandial plasma levels 121serum ghrelin concentration in these three groups was nega-
tively correlated with BMI (Table 2). In lean group ghrelin lev-
els negatively correlated with waist and hip (Table 2). In
overweight group the negative correlation was found only be-
tween ghrelin levels and both BMI and hip (Table 2). In obese
group ghrelin levels negatively correlated with waist, hip (Ta-
ble 2). Ghrelin concentration was declined after the meal in
lean control. Meanwhile slight reduction in overweight and ob-
ese groups was observed. These differences were statistically
signiﬁcant (P< 0.001 and P< 0.05, respectively).
4. Discussion
Several observations from rodent studies support the hypoth-
esis that ghrelin is a physiological meal initiator. First, ghrelin
is synthesized primarily by the stomach (Kojima et al., 1999),
an organ that is well positioned to sense short-term ﬂuxes in
energy balance. Second, despite being produced peripherally,
ghrelin acts centrally to stimulate food intake (Wren et al.,
2000). Third, ghrelin affects feeding rapidly, increasing both
food intake (Asakawa et al., 2001) and gastric acid secretion
within 20 min of intraperitoneal injection (Masuda et al.,
2000). Fourth, exogenous ghrelin triggers eating in rodents
during the day (Wren et al., 2000; Asakawa et al., 2001; Nak-
azato et al., 2001), a time when food intake is usually nominal.
Finally, ghrelin activates hypothalamic neuropeptide
Y/Agouti-related peptide neurons (NPY/AGRP) and increases
AGRPgene expression. AGRP has been implicated as a central
mediator of meal initiation because mRNA levels in the hypo-
thalamus rise shortly before the onset of maximal daily food
intake in ad libitum–fed rats, whereas levels of other neuropep-
tides involved in energy balance are stable throughout the day
(Watson et al., 1999). In this study, we measured the plasma
ghrelin levels in 122 Saudi females and investigated the associ-
ated factors. Our data show that, in lean subjects fasting plas-
ma ghrelin levels were shown to rise nearly twofold before
meal and fall to trough levels within 1 h after eating. The ﬁnd-
ing that preprandial rise and postprandial fall in plasma ghre-
lin levels has been previously demonstrated (Shiiya et al., 2002;
Vicennati et al., 2007), and supports the hypothesis that ghre-
lin plays a physiological role in meal initiation in humans.
In this study, BMI were inversely correlated with fasting
plasma ghrelin levels. This conﬁrmed the view that ghrelin is
closely associated with obesity. Ghrelin has been considered
as a cause of obesity in some studies, on account of the fact
that ghrelin has orexigenic effects in both rats and humans
(Haqq et al., 2003; Tang-Christensen et al., 2004). However,
the results of most studies in humans, similar to ours, have
demonstrated that ghrelin levels are negatively correlated with
BMI (Tritos et al., 2003; Baldelli et al., 2006; Zou et al., 2008).Several studies have reported that fasting plasma ghrelin is
reduced in obese subjects as compared to lean controls (Han-
sen et al., 2002; Broglio et al., 2004; Suematsu et al., 2005). Our
data show that serum ghrelin levels are signiﬁcantly decreased
in obese and overweight subjects and remain decreased after
meal as compared with BMI-matched controls. The absence
of this fall in obese and overweight subjects could demonstrate
impaired suppression of the drive to eat following a meal in
obese subjects leading to increased food consumption and
weight gain.
Currently factors thought to inhibit ghrelin secretion
include leptin, interleukin-1b, GH and high fat diet (Shintani
et al., 2001; Lee et al., 2002). Stimulatory factors appear to
be fasting and a low protein diet These factors may explain
why ghrelin is suppressed in obese subjects but do not explain
the dynamic response of ghrelin to eating, why concentration
of peptide that stimulates gastric emptying (Vicennati et al.,
2007) fall after food ingestion or why these responses are
altered in obese individuals. Zou et al. (2008) speculate that
the lower ghrelin levels in obesity are part of negative feedback
to inhibit appetite and body weight, but not the primary cause
of obesity (McLaughlin et al., 2004). This is also supported by
the fact that circulating ghrelin levels increase in anorexia and
cachexia (Misra et al., 2005; Janas-Kozik et al., 2007). How-
ever, animals without ghrelin do not have signiﬁcantly altered
body weight or food intake when compared with their wild-
type littermates (Sun et al., 2003; Wortley et al., 2004). This
suggests that it is a part of a reversible feedback mechanism,
but not a determinant factor (Zou et al., 2008).
In conclusion, there are profound differences between ghre-
lin baseline concentration and dynamic responses to food in-
take in lean and obese subjects. The fall in plasma ghrelin
concentration in lean subjects may represent suppression of a
hunger signal. The lack of similar fall in obese subjects may
indicate that ghrelin secretion is already maximally suppressed
in this group, or a persistent orexigenic drive, failing to
respond to food intake, that predisposes to obesity. Further
studies are required to investigate the effect and the mechanism
of ghrelin deﬁciency in individuals with obesity.References
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